222. Primary nephrotic syndrome Clinical trials / Disease details

Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02093533 (ClinicalTrials.gov)	March 2014	17/3/2014	Eculizumab in Primary MPGN	EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA	Membranoproliferative Glomerulonephritis	Drug: Eculizumab	Mario Negri Institute for Pharmacological Research	Alexion Pharma Italy s.r.l.	Completed	N/A	75 Years	All	10	Phase 2	Italy
2	EUCTR2013-003826-10-IT (EUCTR)	24/01/2014	28/10/2013	ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS	EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGN	Membranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Soliris Product Name: Soliris INN or Proposed INN: ECULIZUMAB	IRCCS- Mario Negri Institute	NULL	Not Recruiting			Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Italy
3	NCT01221181 (ClinicalTrials.gov)	July 2010	13/10/2010	Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy	Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy	Dense Deposit Disease;Membranoproliferative Glomerulonephritis	Drug: Eculizumab	Columbia University	Alexion Pharmaceuticals	Completed	18 Years	N/A	All	6	Phase 1	United States